Navigation Links
InspireMD Announces Upcoming Investor Event in Israel
Date:11/19/2013

BOSTON, November 19, 2013 /PRNewswire/ --

InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it will host an investor event at the Dan Tel Aviv Hotel in Tel Aviv, Israel on December 2, 2013 at 5:00 p.m. local time.

At the event, the senior management team of InspireMD will review the recently announced 12-month follow up data from its MASTER trial, discuss its recent clinical and operational efforts, and answer questions from the audience.  

Investors wishing to attend the event should RSVP to Bars@inspiremd.com with "Investor Event" in the subject line.

About Stenting and MGuard™ EPS

Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.

In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.

The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.

While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician practice - an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard™ technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures.  InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard™ EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: +1-212-896-1215 / +1-212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: +1-212-896-1216 / +1-212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com


'/>"/>
SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. InspireMD Files At-the-Market Offering and Shelf Registration Statement
2. InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan
3. InspireMD To Participate In Benchmark Investor Conference On May 30th
4. InspireMD Hires Vice President of Corporate Development
5. Michael Berman Joins InspireMD Board
6. InspireMD Postpones $40 Million Registered
7. InspireMD Reports 2012 Fiscal Year Results
8. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
9. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
10. InspireMD Appoints Dr. James Barry to Its Board of Directors
11. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... and READING, England ... Indegene ( http://www.indegene.com ), ein führender ... für die Life-Science-Branche, Pharmaunternehmen und Gesundheitsorganisationen, und ... Anbieter von innovativen wissenschaftlichen Support-Services für den ... von IntraScience heute den Ausbau ihrer bestehenden ...
(Date:5/26/2016)... and READING, England ... Indegene ( http://www.indegene.com ), a leading global provider ... science, pharmaceutical and healthcare organisations and TranScrip ( ... scientific support throughout the product lifecycle, today announced ... launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising ... at the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular ... US earlier this year following FDA approval of a second application for a ...
(Date:5/25/2016)... ... , ... Lajollacooks4u has become a rising hotspot for specialized team building events ... attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have traveled ... , Each event kicks off with an olive oil and salt-tasting competition. From ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
Breaking Biology News(10 mins):